University of Oklahoma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Oklahoma sits in the top decile of US sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count).
University of Oklahoma: 358 sponsored US clinical trials, 80 recruiting.
University of Oklahoma sponsors 358 registered US clinical trials on ClinicalTrials.gov, 80 of them currently recruiting, and 196 completed. 26 of these trials are in Phase 3-4 (later-stage) and 88 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 6 trials.
Top-decile sponsor footprint
University of Oklahoma ranks in the top decile of sponsors by registered trial count (#100 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
196 of 240 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
358 total, page 2 of 8
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT05512208
Oklahoma Study of Native American Pain Risk III: Stress and Resilience
NCT05723081
Pilot Imaging Study of Leukemia
NCT03633955
The Effects of Acute Melatonin Supplementation on Cardiovascular Responses to Sympathetic Activation
NCT04831398
Identify microRNAs in Cachexia in Pancreatic Carcinoma
NCT05275075
The Oklahoma Parent-Child Assistance Program
NCT05534568
Behavioral Activation + Occupational Therapy: An Innovative Intervention for Empowered Self-Management of Multiple Chronic Conditions
NCT05600465
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
NCT05172765
Neuromodulation of Inflammation and Endothelial Function
NCT05230732
Advanced or Recurrent Solid Tumors Treated With SHetA2
NCT04928508
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
NCT05174052
Metabolic Pathology of Pediatric NAFLD
NCT05430178
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671
Endothelial Derived Hyperpolarization Factor and Vascular Control
NCT05176379
Myo-Inositol for Infertility in PCOS
NCT04407754
Autoimmune Basis for Postural Tachycardia Syndrome
NCT05043051
Tribally Engaged Approaches to Lung Screening (TEALS)
NCT04948060
Fatigue and Cognitive Demand With Aging
NCT05121272
High Dose Omeprazole in Patients With Pancreatic Cancer
NCT04930991
Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
NCT03980457
Synaptic Plasticity in the Epicardial Ganglionated Plexi
NCT05034419
REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
NCT03541889
Substance Use Treatment and Access to Resources (STARS) Project
NCT04459000
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
NCT05208671
Pain and Opioid Management in Older Adults
NCT05037682
Ketamine for Post-operative Analgesia in Hemorrhoidectomy
NCT04248205
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
NCT03992378
Outcomes in Simulated Endoscopy Training
NCT03495141
Low Level Tragus Stimulation in Acute Decompensated Heart Failure
NCT02898181
Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma
NCT02241265
AI_Colonoscopy_for_Fellows
NCT07661914
Pilot Window of Opportunity Trial (POET)
NCT06129604
Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial
NCT05784766
Prophylactic DR-CPAP on Late Preterm Infants Born by C-section: an RCT
NCT05204719
Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men
NCT05331638
Wearable Focal Vibration for Chemotherapy-Induced Peripheral Neuropathy
NCT04959929
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
NCT05471128
Mobile Contingency Management for Smoking Cessation
NCT04881630
Resistance Training With Blood Flow Restriction
NCT05863039
Implant Stability in Autogenous Mineralized and Demineralized Dentin Grafts
NCT05219305
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
NCT05863052
Mobile App for Smoking Cessation and Mental Health
NCT04887558
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
NCT04373642
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
NCT04068753
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03932409
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
NCT04004442
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
NCT03771651
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
NCT03587038
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03526432
Exercise and Nutrition to Improve Pancreatic Cancer Outcomes
NCT03256201
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 40 |
| Phase 3 | 8 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the University of Oklahoma pipeline
80 recruiting of 358 indexed (22% open); 196 completed (55%).
Phase mix: 26 late (III/IV) vs 88 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Oklahoma: open-pipeline peers nationwide
Peers matched on 358 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
University of Oklahoma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 358 trials (± recruiting share)
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of Arizona · 349 trials · 16% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this University of Oklahoma page
358 registered trials is a research-attention snapshot, not an endorsement of University of Oklahoma or any single study.
- 80 of University of Oklahoma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Oklahoma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Oklahoma pipeline card: 358 registered trials from official public datasets.Report a data error.